@hswapnil.medsky.socialRethinking Guideline Delivery in Nephrology: From Access to Action - Kidney International Reports www.kireports.org/article/S246...
See #NephJC and @freelyfiltered.bsky.social contribution to guideline dissemination
@kireports.bsky.social from @kidneyboy.bsky.social et al
@nephjc.bsky.social8/10
#NephJC Consensus:
In most cases, DDKT can improve survival compared to continued dialysis.
Not all donor kidneys are created equal (SCD, ECD, DCD, DBD).
Discussion of recipient and donor quality should be undertaken during transplant evaluation, as well of goals of care
@nephjc.bsky.social1/10
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
@nephjc.bsky.socialCheck out the VA by @danyrcal
Do older, sicker patients benefit from kidney transplantation?
This is a nuanced "it depends" answer that is worthy of discussion. #NephSky #NephJC
www.nephjc.com/news/targetva
@nephjc.bsky.socialThis week we are looking at a target trial emulation on transplantation.
Do older patients benefit from kidney transplant?
What if the donation is after: CV death or brain death?
What if the donor is a standard (SCD) or extended (ECD) criteria donor? #NephSky #NephJC
www.nephjc.com/news/transpl...
@nephjc.bsky.social12 years of #NephJC. Countless papers discussed, ideas challenged, and friendships made.
🩵No paywalls. No pharma funding, just a community that believes in free, independent nephrology education.
🌟We need your help to keep it going. Please donate
@rnflex.bsky.socialCan an oral small molecule provide renal and cardiovascular benefits just like the injectable GLP1 meds? The answer is probably so! New blog post today about Achieve 4 and it's CV trial that was presented at EASD. They also looked at it's renal benefits. So shout-out to #NephJC as well.
@edgarvlermamd.medsky.networkSelect RCTs, informing current management strategies for patients with SA-AKI
#Nephpearls #AKIinICU #NephJC #NephSky
@nephjc.bsky.socialCan tolvaptan keep up with 3% saline?
This within-subject study in healthy volunteers delivered a surprising answer - and a few eyebrow-raising physiology twist. Dive in #NephJC
✍️ by @drsaivani.bsky.social
@nephjc.bsky.social8/10 ⚠️ #NephJC Consensus
💡Underpowered (94/114 target, ~75% power), open-label, 2 center trial, wide margin (CI compatible w/ ~14 extra relapses/100 pts short-course), and FSGS trended toward favoring the longer taper underpowered subgroup
💡Hypothesis-generating only
@nephjc.bsky.social7/10
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
@nephjc.bsky.social6/10
Question 1
#NephJC #Nephsky or #NephTwitter
Q: Should we stop steroids quickly in all podocytopathies?
A: Probably not, but this gives us evidence that we should explore this further in larger trial, as less steroids has less AE exposure, but also without more relapses
@nephjc.bsky.social
@divyaveerssneph.bsky.social📢 The New #NephJC VA just dropped in !!!
@kireports.bsky.social
It's a study from @PGINEPHRO and I am a co-author🤩
Thanks to Dr. Raja Ramachandran, Dr. Arun
After obtaining remission, 2 months is non inferior to standard 4 months steroid tapering in podocytopathy.
#Nephbluesky #Nephsky #NephEd
@nephjc.bsky.socialSteroids are useful (and have bad side effects) in patients with podocytopathies.
Starting is easy, but stopping can be challenging.
Are longer courses of steroids better for longer remissions? How quickly do you taper? 🐇🐢
#NephSky #NephJC
www.nephjc.com/news/startsteroidtaper
@manoleaandreea.bsky.social
@farahwehbe92.bsky.social